NCT03680417View on ClinicalTrials.gov

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

PHASE4CompletedINTERVENTIONAL
Enrollment

590

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

February 26, 2018

Study Completion Date

August 1, 2018

Conditions
Safety IssuesImmunogenicity
Interventions
BIOLOGICAL

Measles-Rubella (MR) Vaccine

Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.

Trial Locations (1)

60131

Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ., Surabaya

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
lead

PT Bio Farma

INDUSTRY